{"text": ["Merck's", "Keytruda", "Betters", "Survival", "in", "Lung", "Cancer", "Combo", "Study"], "created_at": "2018-04-17 17:14:04"}
{"text": ["Merck's", "Keytruda", "Betters", "Survival", "in", "Lung", "Cancer", "Combo", "Study"], "created_at": "2018-04-17 17:14:04"}
{"text": ["Novartis\u2019s", "Innovative", "Medicines", "Segment", "in", "1Q18"], "created_at": "2018-04-17 16:40:02"}
{"text": ["Celldex's", "Phase", "II", "Breast", "Cancer", "Study", "Fails,", "Shares", "Plunge"], "created_at": "2018-04-17 16:15:54"}
{"text": ["Celldex's", "Phase", "II", "Breast", "Cancer", "Study", "Fails,", "Shares", "Plunge"], "created_at": "2018-04-17 16:15:54"}
{"text": ["5", "Drug", "Stocks", "Poised", "to", "Surpass", "on", "Earnings", "This", "Quarter"], "created_at": "2018-04-17 15:48:03"}
{"text": ["Celldex&apos;s", "Phase", "II", "Breast", "Cancer", "Study", "Fails,", "Shares", "Plunge"], "created_at": "2018-04-17 13:55:01"}
{"text": ["Expectations", "from", "Novartis\u2019s", "1Q18", "Earnings"], "created_at": "2018-04-17 13:36:50"}
{"text": ["Risankizumab", "Could", "Be", "AbbVie\u2019s", "Long-Term", "Growth", "Driver"], "created_at": "2018-04-17 13:02:26"}
